Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

Primary Immune Deficiency Clinical Trial

Official title:

Prospective, Open-label, Single-arm, Multicentre Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04640142
• Other study ID #: NORM-01
• Status: Recruiting
• Phase: Phase 3
• Start date: August 4, 2021
• Est. completion date: June 2025

Study information

• Verified date: April 2024
• Source: Octapharma
• Contact: Patrick Murphy
• Phone: 866-337-1868
• Email: ctgov[@]clinicalresearchmgt.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: June 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age of =2 years and =75 years

2. Documented and confirmed diagnosis of PID as defined by European Society of Immunodeficiencies (ESID) and the Pan American Group for Immune Deficiency (PAGID) and requiring immunoglobulin replacement therapy due to hypogammaglobulinaemia or agammaglobulinaemia. The exact type of PID must be recorded.

3. At least 12 weeks of regular treatment before the screening visit (i.e., with a stable dosing interval) with any IVIG, SCIG, or fSCIG, with a stable IgG dose between 200 and 800 mg/kg/month. A stable dose is defined as one that deviates less than ±25% from the mean dose for all infusions within this 12-week period before screening.

4. Trough level of IgG =5 g/L at screening and documentation of an IgG trough level of =5 g/L at least once within the previous 12 weeks.

5. Freely given written informed consent from adult patients or freely given written informed consent from the patient's parent(s)/legal guardian(s) and written informed assent from paediatric or adolescent patients in accordance with the applicable regulatory requirements, before any study-specific procedure takes place.

6. Willingness to comply with all aspects of the protocol, including blood sampling, for the duration of the study.

Exclusion Criteria:

1. Any acute infection requiring IV antibiotic treatment within 2 weeks before the screening visit or during the screening period, or any SBI within the 3 months prior to the screening visit or during the screening period.

2. The patient has isolated specific antibody deficiency disorder, isolated IgG subclass deficiency, or transient hypogammaglobulinaemia of infancy.

3. Current medical condition or history of condition known to cause secondary immune deficiency, for example, chronic lymphocytic leukaemia, lymphoma, multiple myeloma, or chronic or recurrent neutropenia (absolute neutrophil count <1000/µL).

4. Known history of ADRs to IgA contained in other products.

5. Body mass index >40 kg/m2.

6. Exposure to blood or any blood product or plasma derivative other than IgG for PID within 3 months before the first infusion of Newnorm.

7. History of or ongoing severe hypersensitivity, e.g., anaphylaxis or severe systemic response, or persistent reactions to blood or plasma-derived products, or to any component of Newnorm (such as glycine).

8. Severe liver dysfunction (alanine aminotransferase [ALT] >3 times the upper limit of normal for the expected normal range for the testing laboratory) at screening.

9. Known protein-losing enteropathies or proteinuria (known urinary protein loss of >1 g/24 h, or dipstick proteinuria of =3+).

10. Moderate to severe renal dysfunction (per investigator discretion based on estimated glomerular filtration rate [eGFR] =44 mL/min/1.73 m2, as defined by KDIGO Clinical Practice Guideline) or predisposition to acute renal failure (e.g., any degree of pre-existing renal dysfunction in presence of additional acute renal failure risk factors, e.g. routine treatment with known nephrotoxic drugs).

11. Uncontrolled diabetes mellitus (HbA1c > 7% / >53 mmol/mol).

12. Uncontrolled arterial hypertension (systolic blood pressure of = 130 mmHg for the subject under 13 years of age, = 140 mmHg for subject 13 to 17 years of age, and > 160 mmHg for adults).

13. Dysrhythmia/Tachycardia (resting heart rate > 100 bpm for adults/adolescents and > 120 bpm for children) and symptomatic bradycardia (resting heart rate < 60 bpm for adults, < 50 bpm for adolescents, and < 75 bpm for children in presence of symptoms e.g., low blood pressure, abnormal rhythm, chest discomfort, shortness of breath). Physiological sinus bradycardia in physically active adults/children/athletes is NOT an exclusion criterion).

14. The subject has a history of or current diagnosis of deep venous thrombosis or thromboembolism (e.g. myocardial infarction, cerebrovascular accident, or transient ischemic attack); history refers to an incident in the year prior to screening or 2 episodes over lifetime.

15. The subject is currently receiving anti-coagulation therapy which would make SC administration inadvisable (vitamin K antagonist, nonvitamin K antagonist oral anticoagulants [e.g. dabigatran etexilate targeting Factor IIa, rivaroxaban, edoxaban, and apixaban targeting Factor Xa], parenteral anticoagulants [e.g. fondaparinux]).

16. Treatment with oral or parenteral steroids either

1. at daily doses >0.3 mg/kg of prednisone (or equivalent) within the last 12 weeks before screening or

2. bolus treatment of a daily dose greater than 1 mg/kg of prednisone (or equivalent) for longer than 10 days within the last 12 weeks before screening. Courses of corticosteroids (intermittent) of not more than 10 days would not exclude a patient. Inhaled or topical corticosteroids are allowed.

17. Treatment with systemic immunosuppressants including chemotherapeutic agents 1 year before screening or immunomodulatory drugs 12 weeks before the screening visit.

18. Live viral vaccination (such as measles, rubella, mumps, or varicella) within 1 month before the first infusion of Newnorm, during the study period, and within 3 months after last infusion of Newnorm. Note: Seasonal inactivated (killed) influenza vaccines (incl. H1N1) are allowed. COVID vaccines (mRNA vaccine and a non-replicating viral vector vaccine) are allowed.

19. Treatment with any investigational medicinal product (IMP) within 3 months before the screening visit.

20. Presence of any condition likely to interfere with the evaluation of Newnorm or with the compliant conduct of the study.

21. Known or suspected abuse of alcohol, drugs, and/or psychotropic agents within 12 months before screening.

22. Known human immunodeficiency virus (HIV)-1/2, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection or positive for HIV-1/2, HBV, or HCV at screening.

23. Women who are breast feeding, pregnant, or planning to become pregnant, or are unwilling to use an effective birth control method (refer to protocol Section 7.4.10.b) while on study and for 30 days following the last dose of study drug.

24. Men who are unwilling to use birth control to prevent pregnancy for the duration of the study (unless the female partner

Related Conditions & MeSH terms

• Immunologic Deficiency Syndromes
• Primary Immune Deficiency
• Primary Immunodeficiency Diseases

Intervention

Biological:
• Newnorm
Newnorm is a 20% human normal immunoglobulin for SC infusion.

Locations

Country	Name	City	State
Germany	Octapharma Research Site	Leipzig
Germany	Octapharma Research Site	Munich
Hungary	Octapharma Research Site	Budapest
Hungary	Octapharma Research Site	Debrecen
Italy	Octapharma Research Site	Napoli
Italy	Octapharma Research Site	Roma
Italy	Octapharma Research Site	Roma
Italy	Octapharma Research Site	Roma
Italy	Octapharma Research Site	Treviso
Poland	Octapharma Research Site	Kraków
Poland	Octapharma Research Site	Warsaw
Slovakia	Octapharma Research Site	Bratislava
Slovakia	Octapharma Research Site	Martin
Ukraine	Octapharma Research Site	Kyiv
Ukraine	Octapharma Research Site	Lviv
Ukraine	Octapharma Research Site	Lviv
United States	Octapharma Research Site	Chicago	Illinois
United States	Octapharma Research Site	Irvine	California
United States	Octapharma Research Site	Kansas City	Missouri
United States	Octapharma Research Site	Los Angeles	California
United States	Octapharma Research Site	Louisville	Kentucky
United States	Octapharma Research Site	Omaha	Nebraska
United States	Octapharma Research Site	Overland Park	Kansas
United States	Octapharma Research Site	Saint Petersburg	Florida
United States	Octapharma Research Site	White Marsh	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Octapharma

Countries where clinical trial is conducted

United States,  Germany,  Hungary,  Italy,  Poland,  Slovakia,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of Serious Bacterial Infections	Rate of SBIs (defined as bacteraemia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess) per person-year on treatment.	52 weeks
Primary	Average total IgG concentration	Average total IgG concentration (Cav) on steadystate dosing.	16 weeks
Secondary	Infections of any type of seriousness	Infections of any type or seriousness (including acute sinusitis, exacerbation of chronic sinusitis, acute otitis media, acute bronchitis, infectious diarrhoea, etc) (total and by category, annual rate)	52 weeks
Secondary	Time to resolution of infections	Time to resolution of infections	52 weeks
Secondary	Use of antibiotics	Use of antibiotics (number of days on antibiotics and annual rate of treatment episodes) characterised as therapeutic or prophylactic use	52 weeks
Secondary	Hospitalisations due to infection	Hospitalisations due to infection (number of days and annual rate)	52 weeks
Secondary	Episodes of fever	Episodes of fever	52 weeks
Secondary	Days lost from work, school, kindergarten, or day care due to infection	Days lost from work, school, kindergarten, or day care due to infection	52 weeks
Secondary	Child Health Questionnaire-Parent Form	Child Health Questionnaire-Parent Form (CHQPF50) for patients <14 years	52 weeks
Secondary	SF-36 Health Survey	SF-36 Health Survey for patients = 14 of age	52 weeks
Secondary	Non-compartmental PK analyses of all available PK profiles (IVIG and SCIG)	Total IgG, IgG subclasses (IgG1, IgG2, IgG3, and IgG4), and antigen specific antibodies against Haemophilus influenzae B (capsular polysaccharide), Streptococcus pneumoniae (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F), cytomegalovirus (CMV), tetanus, and measles	16 weeks
Secondary	IgG Levels	Trough and peak levels of total IgG and IgG subclasses for weekly Newnorm relative to 3- or 4-weekly IVIG dosing	16 weeks